Scancell Holdings PLC's (LON:SCLP) Cliff Holloway talks to Proactive London about the six month period ending ended October 31, 2020, described by Holloway as the 'most transformative period Scancell has ever experienced'.
He highlights their strengthened cash position, 'which has allowed us to accelerate a lot of the activities within the company'.
He talks through the core focus of advancing their key clinical programmes for their novel therapies for cancer and advance its vaccine candidate for coronavirus (COVID-19).